Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna MRNA revealed 13 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $131,905, and 9 were calls, valued at $371,568.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $115.0 for Moderna over the recent three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Moderna's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale trades within a strike price range from $40.0 to $115.0 in the last 30 days.
Moderna Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|
MRNA | CALL | SWEEP | BULLISH | 03/15/24 | $110.00 | $67.2K | 1.7K | 434 |
MRNA | CALL | TRADE | BULLISH | 04/05/24 | $100.00 | $62.0K | 256 | 148 |
MRNA | PUT | SWEEP | BULLISH | 07/19/24 | $95.00 | $43.6K | 847 | 67 |
MRNA | CALL | TRADE | BEARISH | 04/19/24 | $105.00 | $40.3K | 2.4K | 230 |
MRNA | CALL | SWEEP | BEARISH | 03/15/24 | $98.00 | $38.4K | 844 | 124 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
Present Market Standing of Moderna
- Trading volume stands at 2,962,331, with MRNA's price down by 0.0%, positioned at $99.48.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 55 days.
What The Experts Say On Moderna
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $100.66666666666667.
- An analyst from Canaccord Genuity has decided to maintain their Hold rating on Moderna, which currently sits at a price target of $91.
- An analyst from HSBC has revised its rating downward to Reduce, adjusting the price target to $86.
- In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $125.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.